Sidley Represents Bio-Techne in Its US$11.3 Billion Acquisition by Merck KGaA

Sidley represented Bio-Techne Corporation (NASDAQ: TECH), a nearly 50-year-old leading provider of life science tools, analytical technologies, and consumables, in its acquisition by Merck KGaA, a global science and technology company headquartered in Darmstadt, Germany. Merck, subject to customary closing conditions, will acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion.

The Sidley team was led by Beth E. Berg, Michael A. Gordon, and Sally Wagner Partin (M&A and Private Equity), and included Alex Enion, Leila Malek, Jordan M. Lemoine, Jack N. Cadden, Lynzai N. Cutler, Eduardo K. Cavalieri, Natalie Knowles, and James F. Lochrie (M&A and Private Equity); Ken Daly, Jim Lowe, Mary K. Marks, Sarah Scheinman, Fiona Shajko, Ignacio Montaño Díaz, and Chelsey Miao (Antitrust and Competition); Donielle McCutcheon and Trevor L. Wear (Healthcare); Torrey Cope, Josefine Sommer, and Emily Marden (FDA Regulatory); Sven De Knop, Jen Fernandez, James Mendenhall, Maryanne Kamau, Ben Vallimarescu, and Laura Verbeken (Global Arbitration, Trade and Advocacy); Corey Perry, Elizabeth T. Burns, Alexandra M. Peterson, and Liz Eastlund (Employee Benefits and Executive Compensation); Peter McCorkell, Teresa L. Reuter, and Alex Down (Labor, Employment and Immigration); Christian Brause and Greg Featherman (Tax); Kayla M. West (Capital Markets); Colleen T. Brown and Sasha Hondagneu-Messner (Privacy and Cybersecurity); Joshua T. Hofheimer and Zach Johnston (Technology and Life Sciences Transactions); and Elizabeth K. McCloy and Brandon Bryer (Real Estate).